Literature DB >> 4083181

Immunosuppressive activity and toxicity of cyclosporin A in rats pretreated with high dose cyclophosphamide.

P A Brown, A W Thomson, P H Whiting, R J Davidson, J G Simpson.   

Abstract

Cyclophosphamide (Cy; 150 mg/kg) was administered (i.p.) to groups of Sprague-Dawley rats, followed two days later by immunization with ovalbumin (OVA). From that time, cyclosporin A (CsA; 25 mg/kg) or its vehicle was given (p.o.) for a further 13 days. Control animals tested 14 days after immunization, showed strong Arthus-like and modest delayed-type skin reactions to OVA, in contrast to almost total inhibition in animals tested with Cy, CsA or both. Similar effects were observed with respect to serum anti-OVA antibody levels. Despite itself producing lymphopenia, CsA had no additional effect on the lymphocyte depletion caused by Cy. Both drugs, either alone or in combination, caused neutrophilia and monocytosis. An additional eosinophilia due to Cy was prevented by CsA. Cy induced splenomegaly, nodal extramedullary haemopoiesis and increases in both tissue eosinophils and marrow neutrophils. There was also lymphoid depletion in both spleen and lymph nodes which was enhanced by CsA. Thymic lymphoid atrophy was found only when CsA was given. Despite the powerful immunosuppressive properties of both drugs, detailed biochemical and structural analyses showed no other synergistic toxicity, apart from modest hepatic abnormalities. In particular, there was no enhancement of the nephrotoxicity of CsA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4083181     DOI: 10.1007/BF01966684

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  17 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

Review 2.  Immunobiology of cyclosporin A--a review.

Authors:  A W Thomson
Journal:  Aust J Exp Biol Med Sci       Date:  1983-04

3.  Toxicity of the immune suppressant cyclosporin A in the rat.

Authors:  J T Blair; A W Thomson; P H Whiting; R J Davidson; J G Simpson
Journal:  J Pathol       Date:  1982-10       Impact factor: 7.996

4.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

5.  Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

6.  Enhancement of high dose cyclosporin A toxicity by frusemide.

Authors:  P H Whiting; C Cunningham; A W Thomson; J G Simpson
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

7.  Cyclophosphamide pretreatment induces eosinophilia to nonparasite antigens.

Authors:  M A Vadas
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

8.  Hypersensitivity in the small intestinal mucosa. V. Induction of cell-mediated immunity to a dietary antigen.

Authors:  A M Mowat; A Ferguson
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

9.  Immunosuppression with cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anaemia: preliminary studies.

Authors:  J Hows; R Harris; S Palmer; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

10.  Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.

Authors:  H Shulman; G Striker; H J Deeg; M Kennedy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

View more
  1 in total

1.  Borna disease: association with a maturation defect in the cellular immune response.

Authors:  K M Carbone; S W Park; S A Rubin; R W Waltrip; G B Vogelsang
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.